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Abstract: Cholesterol-dependent cytolysins (CDCs) constitute a family of pore-forming toxins
secreted by Gram-positive bacteria. These toxins form transmembrane pores by inserting a large
β-barrel into cholesterol-containing membranes. Cholesterol is absolutely required for pore-formation.
For most CDCs, binding to cholesterol triggers conformational changes that lead to oligomerization
and end in pore-formation. Perfringolysin O (PFO), secreted by Clostridium perfringens, is the
prototype for the CDCs. The molecular mechanisms by which cholesterol regulates the cytolytic
activity of the CDCs are not fully understood. In particular, the location of the binding site for
cholesterol has remained elusive. We have summarized here the current body of knowledge on the
CDCs-cholesterol interaction, with focus on PFO. We have employed sterols in aqueous solution to
identify structural elements in the cholesterol molecule that are critical for its interaction with PFO.
In the absence of high-resolution structural information, site-directed mutagenesis data combined
with binding studies performed with different sterols, and molecular modeling are beginning to shed
light on this interaction.
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1. Introduction
Perfringolysin O (PFO) is the prototypical example of a family of Gram-positive bacterial
pore-forming toxins known as the cholesterol-dependent cytolysins (CDCs) [1–3]. Despite being
present in a broad range of species, most CDCs show an amino acid sequence identity greater than
39% when compared to PFO [2]. The C-terminus (domain 4 or D4) of PFO is responsible for the
cholesterol-dependent membrane binding and is the domain with the highest percentage of amino
acid identity among CDC members. Cholesterol recognition via D4 is a distinguishing feature of
the CDCs. An exception was found for intermedilysin because it uses the human receptor CD59 as
a receptor for membrane targeting [4]. However, intermedilysin still requires cholesterol to form pores
in membranes [5].
It has long been known that a high level of cholesterol is required in membranes to trigger PFO
binding [6–8]. More recently it was shown that how much cholesterol is required to trigger binding
depends on the overall lipid composition of the membrane [9,10]. However, the precise mechanism by
which cholesterol triggers binding and the conformational changes that lead to pore-formation are
unknown. In this work we will review our current knowledge on CDC-cholesterol interaction and
present some additional insights on the interaction between cholesterol and PFO.
1.1. Structural Elements of Domain 4 Involved in Cholesterol Recognition
PFO D4 consists of two four-stranded β-sheets located at the C-terminus of the protein (Figure 1A).
There are four loops that interconnect the eight β-strands at the distal tip of the toxin. These loops insert
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into the membrane upon binding and are presumably responsible for the interaction of the toxin with
cholesterol [11–13]. Two of these loops (L2 and L3) connect β-strands from opposite β-sheets, while
L1 and the undecapeptide connect β-strands from the same β-sheet. L1 and the undecapeptide are
parallel to each other and abutted perpendicularly by L2, forming a pocket in the bottom of the protein
(Figure 1B). The loops that form this pocket are the most conserved segments in D4, and modifications
to any of these three loops affect the cholesterol binding properties of PFO [13–16]. The remaining L3
is less conserved (Figure 1C). Interestingly, a similar loop arrangement has been recently described for
the C-edge loops of the eukaryotic protein arrestin [17], a protein that interacts with G protein-coupled
receptors blocking G-protein-mediated signaling and directs the receptors for internalization.
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A view of the tip of PFO D4 from the bottom showing the loops and undecapeptide color coded as in 
A; (C) Sequence alignment of the 28 CDC family members showing the conserved amino acids boxed 
and with dark grey background. Highly conserved amino acids are shown with a light grey 
background. 
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to be exclusively responsible for cholesterol recognition and binding. This idea was supported by 
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Figure 1. l ti of 4 are highly conserved among CDCs. (A) Cartoon repr sen ation
of the PFO D4 β-sandwic showing the locati n of the loops and the conserved und capeptide.
The undecapeptide was colored red and the loops were color d green (L1), brown (L2), and blue
(L3); (B) A view of the tip of PFO D4 from the bottom showing the loops and undecapepti e color
coded as in A; (C) Sequence alignment of the 28 CDC family members showing the conserve amino
acids boxed and with dark grey background. Highly conserved amino acids are shown with a light
grey background. Protein names were abbreviated as defined in [2].
The undecapeptide is the longest and ost conserved of the four loops. It as originally thought
to be exclusively responsible for cholesterol recognition and binding. This idea as supported by
several studies sho ing that odifications in it greatly decreased the pore-for ing activity of the
protein [14,18–23]. However, more recent studies showed that other loops in D4 are also responsible
for cholesterol recognition [13]. The undecapeptide has now been suggested to play a role in both the
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pre-pore to pore transition [12] and the coupling of monomer binding with initiation of the pre-pore
assembly [24]. Dowd and colleagues recently showed that modification of a charged amino acid in the
undecapeptide (R468) resulted in complete elimination of the pore-forming activity of PFO and had
a significant effect on the membrane binding of the toxin [14,24]. Despite the novel functions assigned
to the undecapeptide, its role in binding cannot be neglected since many modifications to this segment
have been shown to have a significant effect in toxin-membrane interaction [14].
The L3 is located on the far edge of D4, away from a nascent cavity formed by the undecapeptide,
L1, and L2 (Figure 1). Modifications introduced into L3 have been shown either to have a negligible
effect on cholesterol interaction, or to decrease the amount of cholesterol required for binding [13,16,25].
These results suggest that L3 plays a limited role in cholesterol recognition, and its effect on binding
may be related to nonspecific interactions with the membrane that stabilize the bound form of the
monomer (e.g., decreasing the koff).
A suggested cholesterol recognition motif composed by only two adjacent amino acids in L1,
(T490 and L491 in PFO, Figure 1C) [13], is conserved throughout all reported CDCs. Modifications to
these two amino acids greatly affect the binding of the protein to both cell and model membranes [13,26].
These data suggest a prominent role for T490 and L491 in cholesterol recognition, however, other well
conserved amino acids located in proximity of the pocket formed by L1, L2, and the undecapeptide
have not been analyzed yet (e.g., H398, Y402, A404, E458, and P493) and may also contribute to
cholesterol binding.
1.2. The Effects of Membrane Lipids on the Cholesterol Threshold Required for CDC Binding
Cholesterol concentrations of more than 30 mol % are usually required to trigger binding of PFO
to liposomes prepared exclusively with phosphatidylcholine [8,27]. Other CDCs showed similar effects,
for example streptolysin O (SLO) [7], lysteriolysin O [28], and tetanolysin [6]. How much cholesterol is
required to trigger PFO binding (or “cholesterol threshold”) is reduced by the incorporation of double
bonds in the acyl chains of the phospholipids or by replacing phosphatidylcholine by phospholipids
with smaller head groups [9,10,15]. The high level of cholesterol required to trigger PFO binding,
the discovery of cholesterol-rich domains in membranes, and the presence of PFO on detergent
resistant membranes [29] led some researchers to associate PFO binding with the presence of membrane
rafts [30]. However, it is difficult to envision a scenario where cholesterol will be more readily available
to interact with PFO if located in a cholesterol-rich domain where the interaction with other lipids is
stronger. For example, it has been shown that the presence of sphingomyelin (a lipid that interacts with
cholesterol) actually interferes with PFO binding [10]. Recent studies on PFO-cholesterol interaction
suggest that accessibility of cholesterol to the membrane surface is the key factor to trigger PFO
binding [10,15,31,32].
Moreover, despite the influence phospholipids have on the cholesterol-dependent binding of PFO,
their presence is not required since cholesterol alone (in the absence of any other lipid) is sufficient to
trigger PFO oligomerization and formation of ring-like complexes ([33] and references therein).
1.3. Structure Elements of Cholesterol that Influence CDC Activity
Early studies of the inhibition of SLO and PFO hemolytic activity by different sterols revealed
elements of the cholesterol molecule that are critical for its interaction with the CDCs [34–36].
The affinity of the toxin for a particular sterol was indirectly estimated by measuring the hemolytic
activity of the toxin after a pre-incubation with the sterol. It was assumed that the higher the inhibition,
the stronger the affinity for the sterol (Table 1, Figure 2). Results from these studies have been reviewed
by Alouf [37] and are briefly summarized below.
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Table 1. Interaction of different sterols with CDCs.
Hemolysis Inhibition Sterol in Aqueous Buffer Sterol in Liposomes
SLO PFO PFO PFO PFO PFO
Trp D4 NBD D3 Trp D4 Oligo SDS
cholesterol 1.0 1.0 1.0 1.0 1.0 +++
7-dehydrocholesterol (1.7) 0.67 quenched 0.89 quenched
dihydrocholesterol 0.50 0.46 0.83 1.1 +++
β-sitosterol 0.50 0.61 0.59 0.80 0.94 +++
lathosterol 0.50 0.85 +++
allocholesterol 0.40 0.68 ++
desmosterol 0.18 1.2 +++
coprostanol 0.71 0.11 0.65 +
zymosterol 0.61 +
ergosterol 0.10 0.13 quenched 0.44 quenched
fucosterol 0.42
stigmasterol 0.33 0.037 low <0.08
Numbers in the table show the relative effect when compared with the one observed for cholesterol. Hemolysis
inhibition is calculated using the Inhibitory dose 50 (I50) reported for SLO [34] or PFO [36]. Values for the interaction
of PFO with sterols in aqueous buffer were calculated using the concentration of sterol that cause half of the total
change in Trp emission (nPFO, Figure 5 and Ref. [33]) or NBD emission (rPFOV322C-NBD, Figure 6 and Ref. [33]).
Sterol in liposomes values were calculated using the mol % sterol that cause half of the total change in Trp emission
for rPFO [9]. Relative values for rPFO oligomerization were estimated using the SDS-agarose gel electrophoresis
analysis done by Nelson et al. [9].
Figure 2. Chemical structure of the sterols that interacts with the CDCs. The differences from cholesterol
are highlighted in red. Top molecules inhibit/interact strongly, and the ones in the bottom more weakly
(based on data presented on Table 1).
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1.3.1. The Presence of a Lateral Aliphatic Side Chain of Suitable Size at Carbon 17 Is Required
Addition of polar hydroxyl groups at position C25, C26, or C20 of the eight-carbon chain removes
the inhibitory effect (Figure 3). Replacement of the eight carbon acyl chain for a keto group or an acetyl
group removes the inhibitory effect. Sterols with a double bond at C24–C25 (desmosterol) or with
a =CH-CH3 group at C24 (fucosterol) are still inhibitory. Modification of the eight-carbon chain by
introduction of an ethyl group at C-24 (β-sitosterol) is not critical, but the simultaneous addition of
a double bond at C22–C23 and either an ethyl group (stigmasterol) or a methyl group (ergosterol) at
C24 weakens the inhibitory effect (see Figure 2).
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Figure 3. Chemical structure of cholesterol showing the individual rings (A)–(D) and numbered carbon
atoms. Elements identified as critical for the interaction with CDCs are indicated in red.
1.3.2. The Presence of a 3 β-Hydroxy Group on Ring Is Required
The inhibitory capacity of the sterol is removed when the hydroxyl group is eliminated
(cholestane), oxidized (cholestanone), esterified (cholesterol acetate), etherified (cholesterol methyl
ether), or epimerized into alpha position (epicholesterol). Substitution of the hydroxyl group for a thiol
group (thiocholesterol) or chloride (3 chlorocholestene) also removes the inhibitory effect.
1.3.3. An Intact Ring B Is Required
The presence f the A ring with the β-hydroxyl group and the aliphatic chain at carbon 17 are
not s fficient for binding if the B ring is open (cholecalcifer l). However, neither the saturated or
unsaturated state of ring B and t position of double bonds (lathosterol, alloch lesterol, or zymostenol)
nor the stereochemical relationships of rings A and B to each other are critical for inhibition. The 5β-cis
(coprostanol) and 5α-trans (dihydrocholesterol) configurations are both inhibitory.
Similar effects were observed for the inhibitory effect of sterols on SLO and PFO (the inhibition
of 7-dehydrocholesterol was higher for SLO, but the sample used in this study presented 3 spots on
a thin layer chromatography plate, therefore we need to be cautious when considering this result).
An exception was coprostanol, which was a better inhibitor for SLO than for PFO. Interestingly, some
amino acids in L1 and L2 differ between SLO and PFO (Figure 1C), suggesting that these loops may
interact with the B ring of cholesterol.
Som differences were obs rved when the st rols were incorpor ted into model me branes
(Table 1) [9], but in this case one also need to consider the differential interaction that each sterol
may have with the phospholipids. Oligomerization of PFO on liposomes containing ergosterol or
7-dehydrocholesterol was similar to the one observed with cholesterol, but these sterols quenched
the Trp emission [38] and therefore the binding of PFO to liposomes could not be assessed using
Trp fluorescence.
In the present work, we explored the interaction of free sterols in solution with PFO using
the Trp emi sion inc ease that follow D4-sterol interaction [33]. In addition, we study the effect
of sterol-binding in the conformational changes that occur in D3. Finally, molecular modeling was
attempted to offer structural rationale for the observed trends.
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2. Results
2.1. Selective Solubilization of Sterol Aggregates by Methyl-β-cyclodextrin
We have shown that PFO is able to bind to cholesterol aggregates in solution. Cholesterol
aggregates remain soluble in neutral aqueous buffers, but start to precipitate when the cholesterol
concentration reaches the solubility limit (around 4.7 µM) [33,39]. Similar aggregation profiles were
observed when other sterols were added into aqueous buffer up to a concentration of 30 µM (Figure 4A)
with the exception of 22-dehydrocholesterol, where scatter was lower than that observed for the other
sterols used in this study. It is well known that cholesterol interacts with methyl-β-cyclodextrin (mCD),
and the addition of mCD solubilizes cholesterol aggregates and microcrystals (Figure 4B) [33]. While
attempting to repeat the mCD solubilization with other sterols, we noticed that the sole addition
of one or two carbons to C24 in the aliphatic chain of the sterols was sufficient to interfere with
this process. No solubilization was observed for aggregates formed by β-sitosterol, fucosterol,
stigmasterol, or ergosterol (Figures 2 and 4B), but complete solubilization was observed for cholesterol,
7-dehydrocholesterol, and dihydrocholesterol. The scattered light (relative units) for aggregates
formed by 30 µM aqueous solutions of two other sterols lacking modifications to the acyl chain
-22-dehydrocholesterol and epicholesterol- was 71,800 and 186,400, respectively. The scattered light for
both aggregates decreased more than 96% after addition of mCD, in good agreement with the need for
a C20–C25 linear aliphatic chain in the sterol molecule for fast mCD solubilization of sterol aggregates.
Yet, it was reported that mCD can bind some C24 substituted sterols if they are added directly into the
solution containing mCD [40].
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Figure 4. Sterol precipitated when ad ed into s bu fer solution and they were differentially
solubilized by mCD. (A) Scattered light at 50 nm f e us buffer solutions containing the indicated
amount of sterols. Sterols were added from ethanolic solutions incrementally and incubated 5 min at 37 ◦C
before each measurement; (B) mCD (final concentration 3 mM) was added into solutions containing
30 µM sterols and the right angle light scatter measured after 5 min incubation at 37 ◦C. The bars
represent the average of at least two measurements and the error bars correspond to the range. White
bars and black bars represent the scattered light before and after incubation with mCD, respectively.
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The molecular bases for the sterol-mCD interactions are not well understood, but it is clear from
the observations described above that if sterols with group additions to C24 are allowed to form
aggregates, they do not interact with mCD in the same way that they do when directly diluted into
a solution containing mCD. These results suggest that the order of the addition of the sterols and the
protein may influence the outcome obtained for protein-sterol interactions. Therefore, we reasoned
that when studying the interaction of sterols with water soluble molecules (like PFO in these studies)
it would be necessary to add the sterols into a solution containing PFO to minimize the formation of
sterol aggregates, and maximize the exposure of PFO to solubilized sterol monomers.
2.2. PFO Interaction with Free Sterols
Liposomes made with different sterols have also been used to study how modifications to
the cholesterol molecule affect its interaction with PFO. However, in these studies the PFO-sterol
interaction will be influenced by both, the direct interaction (affinity) of the sterol molecule with PFO,
and the interaction of the sterol with other membrane components (phospholipids, sphingomyelin,
etc.). The higher the interaction of the sterol with other lipids, the less available it will be to interact
with PFO. Therefore, to determine what elements of the cholesterol molecule are critical to bind PFO,
it is important to perform these studies in the absence of other lipid components. We have shown that
binding of PFO to cholesterol in aqueous solution produces an increase in Trp emission, similar to the
one observed when the toxin binds to membranes containing cholesterol [33]. We reasoned that the
same emission change could be used to analyze the interaction with other sterols.
The interaction of PFO with sterols was studied following the Trp emission increase that follows
PFO-sterol interaction (Figure 5). No emission increase was observed when PFO was incubated with
non-interacting sterols like epicholesterol (Figure 5) [33]. In this analysis, both dihydrocholesterol
(reduction of the C5–C6 double bond) and β-sitosterol (addition of an iso-propyl group at C24) showed
a concentration-dependent Trp emission profile that was slightly shifted to higher sterol concentration
when compared to the one obtained for cholesterol (Figure 5). Similarly, the concentration-dependent
change when adding fucosterol was shifted to higher sterol concentrations, indicating that the rigidity
introduced by the double bond between C24 and the ethyl group restrict the interaction of the sterol
acyl tail with PFO (see Figure 2). These four sterols showed a similar maximal increase in Trp emission
when added to a final concentration of 10 µM. A lower Trp emission increase was observed when
PFO was incubated with stigmasterol or 22-dehydrocholesterol, suggesting that flexibility between
C20–C22 is important for the interaction of PFO with cholesterol. Surprisingly, no Trp emission
increase was observed for 7-dehydrocholesterol and ergosterol, two sterols that are able to inhibit the
hemolytic activity of PFO (Table 1) [36]. Both of these sterols possess two conjugated double bonds
in the B ring. It has been suggested that this double bond quenches the Trp emission eliminating
the increase produced upon the interaction of PFO with the sterol molecules [41]. Inner filter effect
could also contribute to mask the Trp emission increase because of the overlap between the Trp and
sterol absorption wavelengths (Figure S1). Therefore, a different approach was required to analyze the
interaction of these sterols with PFO.
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Figure 5. Binding of sterols to the PFO derivative containing the native undecapeptide (nPFO) [33].
Trp emission intensity for 0.1 µM nPFO was measured before (F0) and after (F) addition of the indicated
amount of sterol. Each data point shows the average of at least two measurements and their range.
The cholesterol concentration that produced half of the total Trp emission increase for nPFO was
0.5 µM.
The increase in Trp emission that results from the interaction of PFO D4 with cholesterol is
followed by the movement of a short β-strand (β5) in D3 that exposes the monomer-monomer
interface required for oligomer formation [42]. This conformational change can be detected using the
rPFOV322C-NBD derivative. The environment-sensitive NBD fluorescent probe has a high lifetime (~8 ns)
in the monomeric toxin, and NBD lifetime drops to ~1 ns when the protein interacts with cholesterol
or cholesterol containing membranes [33]. A decrease in the fluorescence intensity of the NBD dye
would be indicative of the interaction of PFO with sterols even if the spectroscopic properties of the
sterol molecule interfere with the increase of Trp emission (as it is the case for 7-dehydrocholesterol
and ergosterol). Using this assay, we observed that both 7-dehydrocholesterol (extra double bond in
ring B) and ergosterol (the same extra double bond in ring B plus another double bond at C22 and
a methyl group at C24) triggered the NBD emission decrease when incubated with the rPFOV322C-NBD
derivative (Figure 6A,C). We also tested β-sitosterol and stigmasterol, two sterols that showed a strong
and weak interaction with PFO, respectively (Figure 6B,D). In both cases the decrease in NBD emission
was parallel to the increase of Trp emission. These data indicate that the conformational change in D3
is also a good reporter for the interaction of PFO with different sterols.
Figure 6. Cont.
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Figure 6. Sterol binding to D4 paralleled the conformational change in D3. rPFOV322C-NBD (0.1 µM)
was titrated with (A) 7-dehydrocholesterol, (B) β-sitosterol, (C) ergosterol, (D) stigmasterol, and the
Trp emission intensity and NBD emission intensity were determined in the same sample at each sterol
concentration. Open symbols correspond to a parallel experiment where an identical volume of ethanol
was added (no-sterol control). Trp emission data are shown in red, whereas NBD emission data are
shown in blue. The average of at least two independent measurements and their range are shown.
As a reference, the cholesterol concentration that produced half of the total NBD emission decrease for
rPFOV322C-NBD was 0.8 µM [33].
2.3. Molecular Modeling Rationales for the Observed Cholesterol Structure–Activity Relationship and
Mutagenesis Data
To rationalize the data from both the site-directed mutagenesis studies and Structure–Activity
Relationship (SAR) analysis of sterols, we have undertaken a modeling study using available CDC
structures as receptors and cholesterol as a ligand. The realization that conformational changes need
to occur to create an arrangement capable of association with cholesterol, prompted us to employ
an Induced Fitting Docking (IFD) algorithm [43] (Schrödinger, LLC, New York, NY, USA). The IFD
algorithm iterates docking stages with local minimizations to identify a likely binding site on the
surface of D4. We have selected the following criteria for judging the likelihood of putative binding
arrangements: (i) contact with highly conserved residues of D4 (due to mechanistic similarities in
cholesterol effects among CDCs); (ii) engagement of both the conserved Thr-Leu pair on L1 and
undecapeptide (as determined through site-directed mutagenesis); and (iii) participation of equatorial
hydroxyl, the only polar site in cholesterol, in H-bonding interaction with conserved donors, acceptors,
or both.
Our initial attempts with the PFO structures available from Protein Data Bank (PDB, ID: 1PFO,
1M3I, and 1M3J) failed to yield any reasonable binding arrangements that would satisfy the criteria
stated above. Further analysis of these and other structures of CDCs highlighted the unique
conformation that the undecapeptide adopts in PFO [26,44,45], which is curled up against the exposed
face of the β-sandwich. The undecapeptide is kept in this conformation by an edge-to-face stacking of
conserved W464 with Y432, a residue that is unique to PFO among the various solved CDCs x-ray
structures. This arrangement separates the undecapeptide from L1 with its Thr-Leu pair, critical for
cholesterol association [13], and was, therefore, not as suitable as a starting point for these studies
without undergoing a major conformational reorganization.
As a consequence, we have expanded the search to suitable structural models for docking
studies to all CDCs featuring the intact undecapeptide sequence from PFO. This search yielded eleven
X-ray crystal structures from the PDB with resolutions of at least 3.1 Å: anthrolysin O (1 structure),
listeriolysin O (1), SLO (1), suilysin (1), and pneumolysin (PLY) (7). Unlike the PFO structures, the seven
structures of PLY offered a rather wide diversity of conformational solutions for the undecapeptide
(Figure 7). PLY has a high level of conservation with PFO in the membrane-associating regions (91%
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identity, 97% similarity for the loops in D4, Figure S2). The conformations of the undecapeptide in
PLY ranged from a nearly canonical β-hairpin with 430GLAW433 reverse turn projected away from
L1 (PDB ID: 5CR8) to a significantly more unstructured and relatively unraveled loop with multiple
solvent-exposed peptide bonds (PDB ID: 4ZGH) that increases the density of hydrophobic residues
co-projected toward the membrane (Figure 7). This flexibility is not unexpected for a sequence
that contains amino acids uncommon in turns (Leu, Ala, Trp) and strands (Glu, Cys, Gly) [46].
Gratifyingly, in the latter structure, a largely contiguous hydrophobic pocket at the interface of the L1
and undecapeptide is starting to emerge furnished exclusively with conserved residues, several of
which come from the rearranged undecapeptide.
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The extended binding pose adopted by cholesterol explains the need for the equatorially projected
hydroxyl, which is capable of making multiple H-bonding contacts, unlike a largely occluded axial
hydroxyl in epicholesterol [33]. Two other notable events occur during the IFD search to permit the
association: (i) the terminal residue of the undecapeptide (R437 in PLY and R468 in PFO), a residue
critical for the stability of the toxin structure [47], becomes solvent exposed and opens up the space
between two β-sheets to become available for association with cholesterol; and (ii) the first residue of
the undecapeptide, (E427 in PLY and E458 in PFO), having lost its salt-bridge partner while remaining
in a largely hydrophobic environment is expected to become protonated with a concomitant pKa
shift from ~4.5 in PFO or β-hairpin PLY structures to 6.5 and 7.5 in cholesterol-free and bound
4ZGH-derived models, respectively (Epik, Schrödinger, LCC, New York, NY, USA) [48], making the
binding surface even more hydrophobic and therefore, more welcoming to a ligand as lipophilic as
cholesterol. This observation is consistent with the report of low pH (5.5–6) enhancing PFO–membrane
association [9]. This model provides a valuable set of testable hypotheses for further evolution of our
insight into mechanistically complex events occurring prior to pore formation by CDCs.
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different groups or parts of the molecule are for protein interaction. In this work we reviewed the 
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interaction of free sterols with PFO, a prototypical example of the CDCs. By integrating all the 
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membrane-anchoring mechanism of CDCs. 
Cholesterol and related sterols (Figure 2) are hydrophobic molecules with very low solubility in 
water. These sterols precipitate when their concentration increases above 5 μM (Figure 4A). Cyclic 
sugars, like mCD have been often used to solubilize and transport cholesterol into/from membranes 
[40]. While most aggregated sterols were readily solubilized by mCD, those with bulky substitutions 
into the acyl-tail were not (Figure 4B). It is not clear if sterols with additions to their acyl chain are 
not able to interact with mCD (steric effect) or if the formed sterol aggregates are kinetically trapped 
Figure 8. The IFD-proposed model for the cholesterol–PLY-D4 complex. (A) PLY D4 is shown in
its full size and rendered as molecular surface colored by sequence conservation between PFO and
PLY (red: identical, orange: similar, white: non-conserved). The molecule of bound cholesterol is
shown as green tubes; (B) Close-up of the binding pose predicted by the IFD docking. The binding
site of PLY D4 is rendered as ribbons shown as cyan arrows and grey tubes for β-strands and loops,
respectively. The key contact residues are shown and labeled with sequence positions for PLY and PFO
(in parenthesis). The cholesterol is shown as a green ball-and-stick model, and H-bonds between the
hydroxyl of cholesterol and undecapeptide backbone are shown as yellow dashed lines.
3. Discussion
Despite the various X-ray high resolution structures available for CDCs, the structure of the
toxin bound to cholesterol has remained elusive. The only information available about the interaction
of CDCs with cholesterol has been obtained by combining effects of site directed mutagenesis and
structurally distinct sterols. Site directed mutagenesis provided information about how different amino
acids contribute to cholesterol binding (assuming that amino acid substitutions do not significantly
affect the folding of the protein). The use of different sterols showed how critical different groups or
parts of the molecule are for protein interaction. In this work we reviewed the information collected
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on CDC-sterol interactions and provided some further information about the interaction of free
sterols with PFO, a prototypical example of the CDCs. By integrating all the available data, we
constructed a binding model for cholesterol–D4 complex that satisfies both the previous findings and
those reported herein, and rationalizes the critical need for cholesterol in the membrane-anchoring
mechanism of CDCs.
Cholesterol and related sterols (Figure 2) are hydrophobic molecules with very low solubility
in water. These sterols precipitate when their concentration increases above 5 µM (Figure 4A).
Cyclic sugars, like mCD have been often used to solubilize and transport cholesterol into/from
membranes [40]. While most aggregated sterols were readily solubilized by mCD, those with bulky
substitutions into the acyl-tail were not (Figure 4B). It is not clear if sterols with additions to their acyl
chain are not able to interact with mCD (steric effect) or if the formed sterol aggregates are kinetically
trapped in a meta-stable state. Successful binding of mCD to some of the C24 substituted sterols
suggest that the latter may be the case [40]. More research is required in this area to elucidate the
molecular details for the interaction of sterols with mCD. However, to minimize the potential problems
of working with aggregated sterols in these studies, each sterol was added in small aliquots into
a solution containing monomeric PFO.
Interaction of PFO with sterols was determined by the increase in Trp emission (Figure 5).
Cholesterol, dihydrocholesterol, and β-sitosterol showed a similar profile, which was in agreement
with the results obtained using inhibition of hemolysis (Table 1). Stigmasterol, a poor inhibitor of
hemolysis, showed a small change in the Trp emission. This weak interaction was corroborated
by the small decrease on NBD emission in D3, a conformational change that follows binding
(Figure 6D). A similar low interaction profile was obtained for 22-dehydrocholesterol, suggesting that
free movement around C22 is required to stabilize cholesterol in its binding site. The limited NBD
emission decrease observed for ergosterol suggested an intermediate binding affinity for PFO D4
(similar to that of fucosterol, as determined using Trp emission). Flexibility of the acyl chain seems
to be necessary to accommodate the cholesterol molecule into the D4 binding site. NBD emission
decrease observed for 7-dehydrocholesterol and cholesterol confirmed the similar interaction observed
using Trp emission. In summary, two regions of cholesterol appeared to be critical for the interaction
with PFO, the β-hydroxyl group and the flexibility of the acyl chain around C20–C22 (Figure 3).
The extent of the decrease in NBD emission observed for 7-dehydrocholesterol, β-sitosterol,
ergosterol, stigmasterol, and the non-interacting epicholesterol correlated with the inhibitory properties
of the same sterols when tested using hemolytic activity (Table 1) [33,36]. However, it is possible that
hemolysis inhibition is caused by the irreversible oligomerization of the toxin on sterol aggregates
(as shown previously for cholesterol) [33], and not by the competition between the sterol and cholesterol
for the binding site. The correlation between hemolysis inhibition and cholesterol binding in aqueous
buffer is more apparent than the one observed with liposomes. As mentioned above, the interaction of
the sterols with lipids may complicate the interpretation of sterol effect on toxin binding when using
lipid bilayers.
Binding of a water-soluble PFO monomer to the membrane is diffusional and electrostatic
interactions may play a role since it has been observed that the introduction or elimination of charged
residues alters binding [12,16,24,25,49]. While on the membrane surface, insertion of non-polar and
aromatic amino acids, and/or specific interactions with membrane lipids, help to anchor the protein to
the membrane [50]. However, hydrophobic amino acids are rarely exposed on surfaces of water-soluble
proteins, and therefore conformational changes are required to facilitate the interaction of these residues
with the hydrophobic core of the membrane bilayer. These conformational changes may contribute
to generate a non-polar cavity required to fit a cholesterol molecule. Cholesterol has been found
located into non-polar protein cavities, for example for the lysosomal protein NPC2, responsible for
Niemann-Pick type C disease [51]. No such cavity is apparent in the structure of the water-soluble
monomer of PFO.
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The binding model, which was produced via a systematic survey of conformational states of
undecapeptide (offered by solved crystal structures of related toxins, Figure 7) and flexible docking,
provided a basis for structure-guided rationalization of the cholesterol SAR trends reported herein.
Thus, the conserved Thr-Leu pair from L1, essential for recognition of cholesterol, is engaged in
the model by the bound ligand, while residues within the undecapeptide, interact with cholesterol
via H-bonding contacts through its backbone (Figure 8). The aliphatic–aliphatic contact predicted
by the model to be established between cholesterols’ tail and conserved residues at the junction
of two β-sheets may accounts for double bond intolerance in the tail, which is expected to reduce
conformational flexibility and interfere with the compact interdigitation that the saturated variant is
capable of.
Both the pH effect in association and the critical role for the terminal Arg in the undecapeptide can
be rationalized by the decoupling of the E458/R468 ionic pair (in PFO, see Figure 8) upon cholesterol
recognition. This leads to change in glutamate’s pKa that promotes protonation and reduction in
surface polarity of the cholesterol-binding site. The exposed Arg is, in turn, likely important for
electrostatic contact with the anionic head-groups of membrane lipids.
This binding model also provides the basis for some of the cholesterol-dependent effects observed
when residues in the D4 loops are mutated. For example, T490 in the PFO-cholesterol model is
predicted to be involved in a complex H-bonding network involving both its side chain and backbone
carbonyl and the side chains of T460 and E458 (in its protonated form) from the undecapeptide.
The static model, however, does not provide a simple explanation for the adjacent L491S mutation
that does not significantly change the cholesterol-binding of PFO [25]. This implies a newly found
H-bonding role for the Ser side chain at this position that, in contrast with the reduced affinity observed
for the L491A substitution, conserved the affinity of PFO for cholesterol.
Finally, the cholesterol-assisted quenching of H-bonding capacity of the flexible undecapeptide
may have profound outcome on passive diffusibility of this peptide for anchoring at the membrane.
Attainment of conformations that allow quenching of H-bonding capacity by peptide bond NH groups
has been noted as a critical pre-requisite for passive internalization of cyclic peptides into biological
membranes [52]. The energetic basis for this requirement is found in high energy of desolvation of
fully exposed peptide bonds upon passage from high-dielectric water to the low-dielectric interior of
a membrane that is typically associated with poor membrane permeation of unstructured peptides in
general. Hence, the conformational adaptation of the undecapeptide upon association with cholesterol
predicted by the model accomplishes several transformations that combine to promote anchoring at the
membrane: (i) higher density of hydrophobic residues projected toward the membrane; (ii) enhanced
charge complementarity in the form of exposed R468; and (iii) reduced desolvation costs for the
internalization of undecapeptide via H-bonding quench with the cholesterol’s hydroxyl. While this
model would require further experimental validation, it offers new insights into the D4–cholesterol
interaction than can be capitalized in future studies.
4. Materials and Methods
4.1. Materials
Phospholipids were from Avanti Polar Lipids); β-methyl-cyclodextrin (mCD) from Sigma
C-4555 (mean degree of substitution 10.5–14.7), 7-dehydrocholesterol higher than 98% by HPLC
Fluka, ergosterol 98% by HPLC Fluka, stigmasterol ~95% GC Fluka, β-sitosterol higher than 98%,
and cholesterol from Steraloids.
Preparation of nPFO and rPFOV322C-NBD derivatives was done as described previously [33]. rPFO
refers to the use of the Cys less PFOC459A derivative.
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4.2. Incubation with Sterol Dispersions in Aqueous Solutions
Water-soluble PFO samples (0.3 mL final volume, 0.1 µM final concentration) in buffer C (50 mM
Hepes (pH 7.5), 100 mM NaCl, 0.5 mM EDTA, 1 mM DTT) were equilibrated at 37 ◦C for 5 min before
the net initial emission intensity (F0) was determined (i.e., after blank subtraction). Sterols were then
added to the indicated final concentration, and the sample was then incubated at 37 ◦C for 15 min.
The net emission intensity (F) of the sample was determined after blank subtraction and dilution
correction. Sterols were dissolved in absolute ethanol to 10 mM and diluted with additional ethanol as
necessary. When added to solutions of nPFO or rPFO derivatives, the final concentration of ethanol
was always lower than 5% (v/v). Control samples were incubated with an identical volume of ethanol.
When indicated, sterol aggregates were dissolved by the addition of mCD to a final concentration of
3 mM. mCD was prepared dissolving 83 mg into 1 mL of HBS buffer (Hepes 50 mM pH 7.5, NaCl
100 mM) at 37 ◦C for 15 min, centrifuged full speed in microfuge and filtered using a 0.22 µm Millipore
filter. The solution was stored at 4 ◦C for no more than a month.
4.3. Steady-State Fluorescence Spectroscopy
Intensity measurements were performed using the same instrumentation described
earlier [25,33,53]. The excitation wavelength and bandpass, and the emission wavelength and
bandpass, were, respectively: 470, 4, 530, and 4 nm for NBD; 295, 2, 348, and 4 nm for Trp; 470;
and 500, 1, and 500, 1 nm for right angle light scattering measurements.
4.4. Molecular Modeling
All computational procedures were carried out using Schrödinger’s Small-Molecule Drug Discovery
suite of programs (v. 2016-1, Schrodinger, LLC, New York, NY, USA): Maestro, Protein Preparation
Wizard, Epik, Glide, Prime and Induced Fit. The energy optimized all-atom models were generated via
a protonation state assignment (Epik), missing atom/loop reconstitution (Prime, OPLS3 force field) and
constrained minimization (Prime) sequence within Maestro’s Protein Preparation Wizard. The flexible
docking was initiated by placing the entire loop-region of D4 into a 15 × 15 × 15 Å3 grid box. Residues
within 5 Å of ligand poses obtained with side-chain-free models (Glide) were refined (Prime) through
docking-minimization iterations (Induced Fit).
Supplementary Materials: The following are available online at www.mdpi.com/2072-6651/9/12/381/s1,
Figure S1: Absorbance spectra of sterols in ethanol; Figure S2: Sequence and structure similarity between
D4 domains of PFO and PLY.
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